Journal
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
Volume 43, Issue 1, Pages 27-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2016.09.005
Keywords
Opportunistic infection; Biologics; Tuberculosis; Zoster; Histoplasmosis; Pneumocystosis
Categories
Funding
- BMS
Ask authors/readers for more resources
Patients being treated with biological therapies are at increased risk for serious infections, including opportunistic infections. Although more is known about opportunistic infection risk with older biologics, such as antitumor necrosis factor drugs, there is less knowledge of opportunistic infection risk with newer biological therapies. The incidence of certain opportunistic infections (tuberculosis, herpes zoster, pneumo-cystosis) has been rigorously evaluated in large observational studies. However, data are more limited for other infections (histoplasmosis, nontuberculous mycobacteria). Infectious morbidity and mortality may be preventable with screening and prophylaxis in select populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available